TYBR Health, a medical device and regenerative medicine company, announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the B3 GEL System. B3 GEL is a bioresorbable, flowable gel barrier designed to protect healing tissue planes and preserve mobility following surgeries involving tendons, ligaments, and skeletal muscle.
Health Technology Insights: Tracer, QIAGEN Partner on Blood-Based MRD Test for Tumors
This clearance marks a significant milestone for TYBR Health, enabling a new approach to support functional recovery in musculoskeletal surgery. B3 GEL helps maintain surgical precision by temporarily separating tissues during the early healing phase—without impeding the natural healing process.
“When we started TYBR, it was with a clear purpose: to solve a real, overlooked problem in surgical recovery,” said Tim Keane, PhD, Cofounder and CEO of TYBR Health. “Too often, healing goes unprotected once the procedure ends. B3 GEL™ is designed to fill that gap—working with the body’s biology to protect tissue planes and give surgeons a way to safeguard patient outcomes during the critical early phase of recovery.”
Health Technology Insights: NextGen Healthcare Adds MDP as Investor, Plans Leadership Shift
B3 GEL is composed of a naturally derived extracellular matrix and is applied via TYBR’s proprietary integrated mixer-applicator system. Its flowable format conforms to complex anatomy and can be used in both open and minimally invasive procedures. The blue-colored gel allows for visual confirmation of placement and resorbs completely over time without leaving residual bulk.
Preclinical studies submitted to support clearance demonstrated that B3 GEL reduced tissue binding and supported improved range of motion in treated models, with enhanced flexion and extension compared to controls (data on file).
TYBR Health plans to begin commercial sales of the B3 GEL System by the end of 2025.
Health Technology Insights: MeMed BV Hits 100K Tests with Rapid Diagnostics
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire